logo

Iveric Bio, Inc. (ISEE)



Trade ISEE now with
  Date
  Headline
11/2/2020 7:14:06 AM IVERIC Bio Q3 Net Loss $25.5 Mln Or $0.27/Shr Vs Loss Of $14.4 Mln Or $0.35/Shr Last Year
10/2/2020 8:04:50 AM IVERIC Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/1/2020 8:50:43 AM IVERIC Bio Announces Positive Phase 3 Results For Zimura In Geographic Atrophy Secondary To AMD, In Ophthalmology
8/5/2020 7:29:32 AM IVERIC Bio Q2 Net Loss $18.6 Mln Or $0.32/Shr Vs Loss Of $14.4 Mln Or $0.35/Shr Last Year
6/18/2020 1:02:22 AM IVERIC Bio Prices Public Offering Of 24.53 Mln Shares At $4.100 Per Share
6/15/2020 6:18:59 AM IVERIC Bio Reports Positive 18 Month Results From Phase 3 Clinical Trial For Zimura
6/2/2020 7:35:48 AM IVERIC Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/3/2020 8:06:26 AM IVERIC Bio Announces Fast Track Designation From FDA For Zimura(r) For Geographic Atrophy Secondary To Dry AMD
4/2/2020 8:09:16 AM IVERIC Bio Grants Newly Hired Employees Equity-based Awards
3/23/2020 4:05:12 PM IVERIC Bio Appoints Pravin Dugel As EVP And Chief Strategy And Business Officer
3/18/2020 8:20:18 AM IVERIC Bio Provides Update On Initiation Of Second Pivotal Clinical Trial Enrollment For Zimura
2/27/2020 7:23:29 AM IVERIC Bio Q4 Net Loss $17.5 Mln Or $0.39/Shr Vs Income Of $104.1 Mln Or $2.62/Shr Last Year
1/13/2020 8:16:49 AM IVERIC Bio Announces Design Of Second Pivotal Clinical Trial For Zimura
11/12/2019 7:16:16 AM IVERIC Bio Q3 Net Loss $14.4 Mln Or $0.35/Shr Vs Loss Of $14.7 Mln Or $0.41/Shr Last Year
11/12/2019 7:13:42 AM IVERIC Bio Provides Further Clinical Details And Its Development Strategy For Zimura